CJC-1295 Legal and Patent Challenges: FDA Status, Compounding Rules, and What Patients Need to Know

Is CJC-1295 FDA-approved?

No. FDA reviewed CJC-1295 in December 2024 and found no approved product containing any form of the peptide in Australia, Belgium, Canada, Denmark, France, Germany, Ireland, Italy, Japan, Norway, Spain or the United Kingdom, and none authorized by the European Medicines Agency [1].

CJC-1295 is an investigational long-acting analogue of growth hormone-releasing hormone (GHRH), developed by ConjuChem Biotechnologies of Montreal and first described in 2005 [1][5]. Two forms are described: CJC-1295, a 29-amino-acid GHRH analogue, and CJC-1295 DAC, the same peptide with an extra maleimidopropionic acid-lysine unit at the C-terminal end that lets it bind albumin in blood and last much longer [1][5]. The 2005 rat study that identified the peptide found it in plasma beyond 72 hours [5]; that is animal data, not human.

FDA also noted that CJC-1295 products sold online are mostly labeled 'research use only', often in blends with ipamorelin and other GHRPs, and that the peptide has turned up in illicit sports use [1]. A research-use-only product is not an approved drug [1].

What FDA's compounding lists say

FDA keeps a list of bulk drug substances for state-licensed pharmacies and physicians, sorted into three categories, and CJC-1295 appears in none of them (list updated May 14, 2026) [2]. It is also absent from the corresponding list for outsourcing facilities (updated March 21, 2025) [3]. It is not a component of an FDA-approved drug and has no USP monograph, so FDA's category 1 policy, under which the agency generally does not act against compounders that meet the stated conditions, does not apply to CJC-1295 [2][3].

Why it sits in the withdrawn table, not category 2

FDA's page on bulk substances that may present significant safety risks (content dated 04/22/2026) puts CJC-1295 in the 'nominated but withdrawn' table [6]. It had been in category 2 and came off that list because the nominators withdrew their nominations [6]. FDA's concerns remain posted on the page:

• possible immunogenicity for certain routes of administration
• impurity and characterization problems
• 'serious adverse events associated with CJC-1295 including increased heart rate and systemic vasodilatory reaction'
• 'available clinical data are limited' [6]

The December 2024 advisory committee vote

On December 4, 2024, FDA's Pharmacy Compounding Advisory Committee voted on whether the peptide should be added to the pharmacy bulks list: 0 yes and 13 no on CJC-1295 free base, 1 yes and 12 no on CJC-1295 acetate, and 0 yes and 13 no on each of the three DAC forms [7]. FDA's reviewers had proposed that none of the forms be added [7].

Does the October 2026 HHS peptide policy cover it?

No. HHS's October 2026 draft enforcement-discretion policy names six peptides: BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500 [4]. CJC-1295 is not one of them, and no FDA or HHS action allowing CJC-1295 to be compounded has been identified [4].

The clinical record behind that regulatory position

FDA identified only three published human studies of CJC-1295, all of the DAC form and all in healthy volunteers: Teichman 2006, Ionescu and Frohman 2006, and Sackmann-Sala 2009 [1]. It found no study of any form in people with a disease [1]. One trial in HIV-associated visceral obesity listed on ClinicalTrials.gov (NCT00267527) was terminated [1].

FDA's briefing says ConjuChem withdrew CJC-1295 DAC from clinical trials in 2006 after a participant in a phase 2 trial in HIV lipodystrophy, which enrolled 192 people, died [1]. FDA cites news reports: the person had chest discomfort 2 hours after an 11th weekly dose, an ECG showed an acute heart attack, and the attending physician's most likely explanation was undiagnosed coronary artery disease with plaque rupture [1]. The data were never published, so whether CJC-1295 caused the death is neither shown nor excluded [1].

Teichman 2006 remains the main controlled dataset. It was two randomized, placebo-controlled, double-blind, ascending-dose trials lasting 28 and 49 days in healthy adults aged 21 to 61, with single doses in the first study and two or three weekly or biweekly doses in the second [9]. Doses ran from about 30 to 250 micrograms/kg [1][9]. After a single injection the estimated half-life was 5.8 to 8.1 days, mean plasma GH rose 2- to 10-fold for 6 days or more, and mean IGF-I rose 1.5- to 3-fold for 9 to 11 days; after multiple doses IGF-I stayed above baseline for up to 28 days [9]. No serious adverse reactions were reported [9].

Per FDA's summary of those trials, injection-site reactions occurred in about 70% of treated subjects in study 1 and in all treated subjects in study 2; headache occurred in 63% versus 14% on placebo in study 1; flushing, warmth and transient low blood pressure occurred in about 30% of treated subjects in study 1; there was transient diarrhea and, in two subjects, transient dizziness and low blood pressure [1][9]. Most events were more common at 125 or 250 micrograms/kg [1].

In Ionescu and Frohman 2006, healthy men aged 20 to 40 received one injection of 60 or 90 micrograms/kg; GH pulse frequency and size were unchanged, trough GH rose about 7.5-fold, mean GH rose 46% and IGF-I 45% [10]. Dose-dependent increases in heart rate and transient injection-site redness and tenderness were reported, with no serious adverse events [1].

FDA's wider concern is the class effect: GH and IGF-I elevation carries the risks printed on approved growth hormone labels, such as glucose intolerance and diabetes, fluid retention and tumor growth concerns, and the CJC-1295 studies were short, small and mostly single-dose, so long-term safety is unknown [1].

Is there a recommended dose?

There is no FDA-approved dose for CJC-1295. Human studies used single subcutaneous doses of about 30 to 250 micrograms/kg, or two to three doses given weekly or every two weeks; these were study doses, not recommended doses [1][9].

Sport

WADA's 2026 Prohibited List names CJC-1295 and CJC-1293 in section S2.2.4 as growth hormone-releasing hormone analogues, prohibited at all times in and out of competition, and classifies S2 substances as non-Specified [8]. The 2027 List, in force January 1, 2027, also names it [12].